دورية أكاديمية

转录因子二聚化配体3(TFDP3)在乳腺癌组织中的表达及其与乳腺癌分子分型的相关性研究

التفاصيل البيبلوغرافية
العنوان: 转录因子二聚化配体3(TFDP3)在乳腺癌组织中的表达及其与乳腺癌分子分型的相关性研究 (Chinese)
العنوان البديل: The Expression of TFDP3 in Breast Cancer and Its Role of Breast Cancer Molecular Classification. (English)
المؤلفون: 陈雪, 初明, 杨珂, 阴凯麟, 何嘉勰, 徐兰, 焦运燊, 丁羚昱, 刘彦辰, 初正云, 王月丹
المصدر: Progress in Modern Biomedicine; 2017, Vol. 17 Issue 1, p1-6, 6p
الملخص (بالإنجليزية): Objective: The object of this study is to analysis the expression of cancer testis antigen TFDP3 in breast cancer, to explore the correlation between TFDP3 and development of breast cancer. Methods: The expression of TFDP3 was detected in pathological section of tumor tissues from patients with breast cancer using immunohistochemical method. And we analyzed the data with clinical information of patients to discover the correlation of TFDP3 and the molecular classification of breast cancer. We also detected the expression of TFDP3 protein in five breast cancer cell lines, including MDA-MB-231, MCF-7, SK-BR-3,T47D and MCF-10A, using Western Blot.Then we verified the location of TFDP3 protein in cells through immumofluorescence method. Results: TFDP3 is greatly and broadly expressed in many cell lines and breast cancer tissues, such as breast, lymph node,hypothyroid, appendix and so on, while TFDP3 is 49% percent positive in breast cancer. The expression of TFDP3 is unrelated with clinical stage, pathology type and molecular classification of breast cancer, but related with special tumor marker HER2. Conclusion: TFDP3 highly expresses in breast cancer is related with the expression of HER2. It suggests that TFDP3 be a new potential target molecule of immunotherapy for breast cancer [ABSTRACT FROM AUTHOR]
Abstract (Chinese): 摘要: 目的:本研究旨在分析总结癌-睾丸抗原TFDP3在乳腺癌中的表达规律,探究TFDP3表达与乳腺癌分型及发病进程关系.方法:通过对不同分型及分期的乳腺癌组织切片进行免疫组化检测,分析TFDP3在其中的表达情况,并结合样本来源患者的临床信息,对TFDP3的表达与乳腺癌分子分型、分期及预后的相关性进行统计分析.同时,通过Western Blot检测了5种乳腺癌细胞系(MDA-MB-231、MCF-7、SK-BR-3、T47D及MCF-10A)中TFDP3的表达情况,并通过细胞免疫荧光实验,检测TFDP3在细胞中的定位.结果:TFDP3在已检测的乳腺癌样本中的表达率为49%.乳腺癌临床分子分型标记物HER2的表达与TFDP3的表达呈正相关,但乳腺癌的分期、临床病理分型以及临床分子分型标记物ER、PR的表达均与肿瘤组织中TFDP3的表达无相关性.结论:TFDP3在各在乳腺癌组织中高表达,其表达量与HER2的表达量呈正性相关.这为研究已TFDP3为靶点的乳腺癌免疫治疗,提供了新的依据. [ABSTRACT FROM AUTHOR]
Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
قاعدة البيانات: Complementary Index
الوصف
تدمد:16736273
DOI:10.13241/j.cnki.pmb.2017.01.001